Genticel focuses on curing HPV before it turns into cervical cancer

May 26, 2015 News BioVox

70% of cervical cancer cases are caused by human papillomavirus (HPV) and the traditional HPV vaccines are only useful to prevent, not to treat the infection. Genticel (GTCL) is developing a solution for those who had been previously infected with HPV, and for whom the vaccine would no longer be active, including most adult women carrying the cancerogenic HPV-virus. The company is developing innovative immunotherapies that will work by avoiding cancers that are caused by HPV. They are focusing specifically on preventing cervical cancer by eliminating HPV infection. ProCervix, a therapeutic vaccine currently in the Phase 2 of clinical trials, aims at treating the infection before it turns into cancer. This is a first-in-class immunotherapeutic candidate and a potential blockbuster that could reach about 1 billion euro sales.

The French biotech company Genticel, founded by the Belgian Benedikt Timmerman – former senior director R&D of Novartis Seeds is currently expanding beyond Europe. To obtain licensing revenue from other applications and to increase the visibility for their technology platform on the international market, Genticel has signed a partnership

Avatar photo

With a local focus and global reach, BioVox shares insights into the Belgian life sciences ecosystem with an ever-growing global community. BioVox is a non-profit project: we are able to provide our community with free, quality content because of the generous support of Turnstone Communications and its clients. Our articles bring you hidden opportunities and exclusive insights into the latest research and industry trends!

All posts